Collegium Pharmaceutical Garners $50,000,000 New Round

  • Feed Type
  • Date
    3/11/2015
  • Company Name
    Collegium Pharmaceutical
  • Mailing Address
    780 Dedham Street Canton, MA 02021 USA
  • Company Description
    Collegium Pharmaceutical is dedicated to the development of proprietary, late stage pharmaceutical products that add market value and clinical benefit to existing drugs.
  • Website
    http://www.collegiumpharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $50,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Collegium plans to use the proceeds of this financing to advance its lead abuse-deterrent product candidate, Xtampza ER (oxycodone extended-release capsules), through potential FDA approval and commercial launch as well as to fund operational growth and other pipeline development programs.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy